#17: OSCI News Ramoplanin Demonstrates High Activity Against Wide Array of Isolates of C. difficile, Including Emerging Strains; Data presented at 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
WASHINGTON--(BUSINESS WIRE)--Dec. 18, 2005--Researchers at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) have presented new data today on the in vitro activity...
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 9, 2005-- -- Leading scientific conference features data on clinical efficacy and in vitro activity of FDA-approved fluoroquinolone as well as novel data...
#15: OSCI News Oscient Pharmaceuticals to Present at First Albany Capital Annual Growth Conference; Webcast of presentation available Tuesday, December 6, 2005 at 3:20 PM ET
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 29, 2005--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the 2005 First Albany Capital Annual Growth Conference on December 6, 2005 in...
#14: OSCI News Oscient Pharmaceuticals Reports Financial Results for Third Quarter of 2005; Conference Call with Senior Management Scheduled for 8:30 AM ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 2, 2005--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the third quarter ended September 30, 2005. During this...
#13: OSCI News Oscient Pharmaceuticals to Present Clinical Data on FACTIVE(R) Tablets at Chest 2005; Data Presentations Address Utility of FACTIVE in High-Risk Patients and against Resistant Infections
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 25, 2005--Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will release financial results for the third quarter ended September 30, 2005 on Wednesday,...
#11: OSCI News Oscient Pharmaceuticals to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference; Webcast of presentation available Wednesday, October 26, 2005 at 8:20 AM ET
SAN FRANCISCO--(BUSINESS WIRE)--Oct. 7, 2005-- Program includes meta-analysis of clinical trial data in acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis in...
#9: OSCI News Oscient Pharmaceuticals Completes Sales Force Expansion; Company enters respiratory tract infection season with 300 representatives in field
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 3, 2005--Oscient Pharmaceuticals (Nasdaq: OSCI) has expanded the number of primary care pharmaceutical sales representatives detailing its products to 300. The...
WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 30, 2005--Oscient Pharmaceuticals (Nasdaq: OSCI) has filed a shelf registration statement with the Securities and Exchange Commission (SEC) that when declared...
#6: OSCI News Full Results Released from Phase III Trial Comparing Five-Day and Seven-Day Treatment of FACTIVE(R) Tablets for Community-Acquired Pneumonia; FACTIVE demonstrates high rates of clinical success against CAP
MONTREAL--(BUSINESS WIRE)--Sept. 18, 2005--Data from the study of Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, for...
WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 2, 2005-- - Webcast of presentation available Friday, September 9, 2005 at 9:10 AM ET - Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will...
#4: OSCI News Oscient Pharmaceuticals to Present at Roth Capital Partners New York Conference; Webcast of Presentation Available Wednesday, September 7, 2005 at 2:00 PM ET
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 31, 2005--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Roth Capital Partners New York Conference on September 7, 2005 in New...
#3: OSCI News Oscient Pharmaceuticals Reports Financial Results for Second Quarter of 2005; Conference call with senior management scheduled for 8:30 AM ET today
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2005--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the second quarter ended June 30, 2005. During this period,...
